JP6722453B2 - 抗不安薬組成物、製剤および使用方法 - Google Patents

抗不安薬組成物、製剤および使用方法 Download PDF

Info

Publication number
JP6722453B2
JP6722453B2 JP2015528691A JP2015528691A JP6722453B2 JP 6722453 B2 JP6722453 B2 JP 6722453B2 JP 2015528691 A JP2015528691 A JP 2015528691A JP 2015528691 A JP2015528691 A JP 2015528691A JP 6722453 B2 JP6722453 B2 JP 6722453B2
Authority
JP
Japan
Prior art keywords
anxiety
administration
disorder
treatment
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015528691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501828A5 (2
JP2016501828A (ja
Inventor
スチュアート エル ウェグ
スチュアート エル ウェグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016501828A publication Critical patent/JP2016501828A/ja
Publication of JP2016501828A5 publication Critical patent/JP2016501828A5/ja
Application granted granted Critical
Publication of JP6722453B2 publication Critical patent/JP6722453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015528691A 2012-08-23 2013-08-23 抗不安薬組成物、製剤および使用方法 Active JP6722453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
US61/692,380 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018124196A Division JP6771512B2 (ja) 2012-08-23 2018-06-29 抗不安薬組成物、製剤および使用方法

Publications (3)

Publication Number Publication Date
JP2016501828A JP2016501828A (ja) 2016-01-21
JP2016501828A5 JP2016501828A5 (2) 2016-10-13
JP6722453B2 true JP6722453B2 (ja) 2020-07-15

Family

ID=50148531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015528691A Active JP6722453B2 (ja) 2012-08-23 2013-08-23 抗不安薬組成物、製剤および使用方法
JP2018124196A Active JP6771512B2 (ja) 2012-08-23 2018-06-29 抗不安薬組成物、製剤および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018124196A Active JP6771512B2 (ja) 2012-08-23 2018-06-29 抗不安薬組成物、製剤および使用方法

Country Status (11)

Country Link
US (4) US20140057988A1 (2)
EP (2) EP2887930A4 (2)
JP (2) JP6722453B2 (2)
KR (1) KR20150096370A (2)
CN (1) CN104902883A (2)
AU (1) AU2013305580A1 (2)
BR (1) BR112015003796A2 (2)
IL (1) IL237340A0 (2)
MX (1) MX2015002378A (2)
SG (1) SG11201501292UA (2)
WO (1) WO2014031975A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116251084A (zh) * 2013-03-15 2023-06-13 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
CN106714789A (zh) 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
EP4023222B1 (en) * 2015-09-08 2024-12-18 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activator for treatment of 22q syndrome
EP3377050A4 (en) * 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3075038B1 (fr) * 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
MX2021010006A (es) 2019-02-22 2021-09-21 Harima Chemicals Inc Metodo de aplicacion de material solido de soldadura fuerte, metodo de produccion de pieza de trabajo recubierta, aparato de aplicacion y material solido de soldadura fuerte en forma de rollo.
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms
PT3976012T (pt) * 2019-05-31 2024-04-09 Afyx Therapeutics As Administração intranasal de cetamina a doentes com cefaleia em salvas
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
WO2007111880A2 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
CN101765582A (zh) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
EP2887930A1 (en) 2015-07-01
JP2016501828A (ja) 2016-01-21
JP6771512B2 (ja) 2020-10-21
US20140057988A1 (en) 2014-02-27
CN104902883A (zh) 2015-09-09
WO2014031975A1 (en) 2014-02-27
US20180235906A1 (en) 2018-08-23
IL237340A0 (en) 2015-04-30
JP2018162302A (ja) 2018-10-18
MX2015002378A (es) 2015-09-25
EP3878442A1 (en) 2021-09-15
SG11201501292UA (en) 2015-05-28
KR20150096370A (ko) 2015-08-24
AU2013305580A1 (en) 2015-04-09
EP2887930A4 (en) 2016-03-23
US20250255834A1 (en) 2025-08-14
US20220160655A1 (en) 2022-05-26
BR112015003796A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
JP6722453B2 (ja) 抗不安薬組成物、製剤および使用方法
Giacoppo et al. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
RU2769397C2 (ru) Композиции и способы лечения передозировки опиоидами
US9592207B2 (en) Intranasal administration of ketamine to treat depression
JPH10500664A (ja) 痛みの管理及び解毒のための鼻腔及び眼球へのケタミン投与
JP2007517049A (ja) 再発性病状を治療するための組成物および方法
Lee et al. Intranasal administration of dexmedetomidine (DEX) as a premedication for pediatric patients undergoing general anesthesia for dental treatment
Chopra et al. Buccal midazolam spray as an alternative to intranasal route for conscious sedation in pediatric dentistry
TW200918048A (en) Drug combinations for the treatment of sialorrhoea
Brent The management of pain in the emergency department
Moore et al. Multidrug intravenous sedation: determinants of the sedative dose of midazolam
US20250275930A1 (en) Transdermal delivery patch for treating pain
JP2016535027A (ja) 非角化重層上皮（ＮＫＳＥ）組織の不快感の治療用局所薬としての１−ジ（ｓｅｃ−ブチル）−ホスフィノイル−ペンタン（ＤＡＰＡ−２−５）
Ishida et al. Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis
JP7369523B2 (ja) 中等度～重度のインフルエンザの処置
Esmat et al. Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy, a double-blind, placebo-controlled trial
WO2007033400A1 (en) Method of treating pain in patients
Busara Sirivanasandha et al. Recovery profiles after general anesthesia in patients undergoing anterior cervical discectomy and fusion (ACDF) surgery with or without dexmedetomidine as an anesthetic adjuvant: a double blinded randomized study
Klick et al. Pediatric procedural sedation, analgesia, and anxiolysis
US20240173308A1 (en) System, method, and treatment for the overdose of xylazine containing substances
Wong et al. Sedation and Analgesia for HIFU Ablation
JP2017538777A (ja) テトラカインをベースにした麻酔剤
CN115697346A (zh) 适应障碍的治疗
Iniya et al. Conscious sedation for cataract surgery done under retrobulbar block–a comparative study evaluating the effects of midazolam and dexmedetomidine
US20150335677A1 (en) Argon is a mu opioid receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180903

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20181019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200622

R150 Certificate of patent or registration of utility model

Ref document number: 6722453

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250